Loading
Nerve Injury and Regeneration / RNA Interference and Gene Delivery · Journal article
Biological and Pharmaceutical Bulletin · September 11, 2026
Raises a question worth testing. It does not answer one.
This is an in vitro proof-of-concept study proposing that substitution of arginine with homoarginine in oligoarginine cell-penetrating peptides enhances intracellular uptake and serum stability. The work is mechanistic and demonstrates potential utility in boron neutron capture therapy in cell culture, but lacks clinical relevance, quantitative reporting, and validation in higher-order models.
In vitro experimental study. Cancer cells in culture. Intervention: l-homoarginine-substituted hexa-oligoarginine cell-penetrating peptide. Compared with: l-β-homoarginine-extended and unmodified hexa-oligoarginine.
l-homoarginine substitution increased intracellular uptake of hexa-oligoarginine compared to l-β-homoarginine extension l-homoarginine incorporation improved short-term stability in fetal bovine serum l-homoarginine-containing peptide facilitated intracellular delivery of boron-containing agents and increased cancer cell killing upon thermal neutron irradiation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Early-stage mechanistic study demonstrating a chemical modification strategy for cell-penetrating peptides in cell culture; no clinical outcomes or human data reported.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The use of cell-penetrating peptides (CPPs) for the intracellular delivery of pharmaceuticals has progressed from basic research to global clinical studies. In this study, we investigated the effects of introducing l-homoarginine into the CPP oligoarginine on intracellular uptake and membrane permeability efficiency. We demonstrated that extending the arginine side chain by one methylene group (l-homoarginine) significantly increased the intracellular uptake of hexa-oligoarginine compared with extension of the main chain by one carbon atom (l-β-homoarginine). Incorporation of the l-homoarginine sequence improved the short-term stability of hexa-oligoarginine in fetal bovine serum. Furthermore, this strategy showed potential utility in boron neutron capture therapy; when used as an intracellular delivery vehicle, the l-homoarginine-containing peptide facilitated the intracellular delivery of therapeutic boron-containing agents and the effects of thermal neutron irradiation, resulting in increased cancer cell killing. These findings demonstrate that the introduction of l-homoarginine residues is an effective approach for improving the intracellular delivery efficiency and biological stability of CPPs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.